BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders
BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.
BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.